

Drug Development Programs Planned and Managed by Dr M J VandenBurg

Phase IIa

Go/No-go studies for:

A potassium channel activator
Calcium sensitiser
Insulin sensitiser
Anti-anginal
Anti-rheumatic disease modifier
Obsessive compulsive disorder
Anti-depressant
Anti-asthmatic
H₂ antagonist
Many anti infectives
Drugs for hypertension
 Heart failure
 Angina and
 Arrhythmias
Impotence

NSAID's
Oral inotropes for CHF
Anti nausea drugs
Drugs for pain
Peripheral vascular disease
Homeopathic for flu
Irritable Bowel Syndrome
Alcohol abuse

Phase III programs for:

Three converting enzyme inhibitors
H₂ antagonist
Many anti-infectives
Potassium channel activator
Non-steroidal anti-inflammatory drugs
Vaccines for Hepatitis B

Beta-blocker
Anti-cancer agents
Aids therapy
Alcohol Addiction
Parkinson's therapy
Wound dressings
Raised IOP

Phase IV programs:

Anti hypertensives
Antibiotics
H₂ antagonist
Non-steroidal anti-inflammatory drugs
Anti-anginal
Anti-Bleeding Compounds.
Diuretic

Analysis, Study Reports, Safety and Efficacy Summaries, IND safety updates, NDA Filings and European Clinical Expert Report for:

Anti-arrhythmic
Hypnotic
Anti-epileptic
Anti-Infective

Complete European submissions for:

Anti-hypertensives
Anaesthetics
Drugs for heart failure,
Angina
Anti-cancer agents
Anti-anaemic products
Drugs for bladder outflow
Anti-platelet agents
Antihistamines

Safety reports for many drugs relating to:

Cardiac, Hepatic, Renal and Photo Toxic Safety Issues as well as safety in stomach and colon

Only the major programs have been listed, single studies and consultancy projects have been carried out in almost all therapeutic areas as well as some niche areas such as:

- ***Cachexia in Aids***
- ***Gene Therapy***
- ***Autologous Transplantation and transfusion***
- ***Blood substitutes***
- ***Wound Growth Modifiers***
- ***Anti oxidant in cardio vascular disease***
- ***Alzheimer's***
- ***Hepatitis A and B***
- ***Anti-fungal***
- ***Syrogens Syndrome***
- ***Anti-thrombotics***